Edition:
India

INSYS Therapeutics Inc (INSY.OQ)

INSY.OQ on NASDAQ Stock Exchange Global Market

7.52USD
1:30am IST
Change (% chg)

$-0.14 (-1.83%)
Prev Close
$7.66
Open
$7.67
Day's High
$7.70
Day's Low
$7.38
Volume
40,671
Avg. Vol
134,311
52-wk High
$14.00
52-wk Low
$4.10

Latest Key Developments (Source: Significant Developments)

Insys Therapeutics Reports First Quarter 2018 Results
Wednesday, 9 May 2018 

May 8 (Reuters) - INSYS Therapeutics Inc ::INSYS THERAPEUTICS REPORTS FIRST QUARTER 2018 RESULTS.Q1 LOSS PER SHARE $0.28.Q1 REVENUE $38.5 MILLION VERSUS $51.8 MILLION.Q1 REVENUE VIEW $25.7 MILLION -- THOMSON REUTERS I/B/E/S.Q1 EARNINGS PER SHARE VIEW $-0.18 -- THOMSON REUTERS I/B/E/S.Q1 ADJUSTED LOSS PER SHARE $0.19.NET REVENUE IN Q1 WAS $23.9 MILLION.  Full Article

Insys Says Working With Authorities To Resolve Issues Related To "Inappropriate Actions" Taken By Former Employees​
Monday, 19 Mar 2018 

March 19 (Reuters) - Insys Therapeutics Inc ::INSYS THERAPEUTICS REITERATES COMMITMENT TO COMPLIANT AND ETHICAL BUSINESS PRACTICES AND ADVANCING INNOVATIVE PRODUCT PIPELINE.INSYS THERAPEUTICS - ‍ALSO CONTINUE WORKING WITH AUTHORITIES TO RESOLVE ISSUES RELATED TO "INAPPROPRIATE ACTIONS" TAKEN BY FORMER EMPLOYEES​.INSYS THERAPEUTICS SAYS ‍LAST WEEK'S FEDERAL INDICTMENTS OF FIVE NEW YORK PHYSICIANS INVOLVE ALLEGATIONS RELATED TO FORMER EMPLOYEES​.INSYS THERAPEUTICS INC - STATEMENT AFTER ‍LAST WEEK'S FEDERAL INDICTMENTS OF FIVE NEW YORK PHYSICIANS INVOLVE ALLEGATIONS RELATED TO FORMER EMPLOYEES​.  Full Article

Neopharm to pay annual cash dividend as 500 won/share for 2017
Tuesday, 13 Mar 2018 

March 13 (Reuters) - Neopharm Co Ltd <092730.KQ> ::Says it plans to pay annual cash dividend as 500 won/share to shareholders of record on Dec. 31, 2017.  Full Article

Insys Therapeutics Voting Trust Reports 58 Pct Stake In Insys As Of Feb 27
Friday, 9 Mar 2018 

March 8 (Reuters) - Insys Therapeutics Inc ::INSYS THERAPEUTICS INC VOTING TRUST REPORTS 58 PERCENT STAKE IN INSYS THERAPEUTICS AS OF FEB 27 - SEC FILING.INSYS THERAPEUTICS INC VOTING TRUST - NASDAQ AND U.S. DOJ REQUESTED THAT TRUST BE ENTERED INTO AND SHARES OWNED BY BENEFICIARIES BE PLACED INTO THE TRUST.INSYS THERAPEUTICS INC VOTING TRUST - TRUST IS IN ORDER TO LIMIT VOTING POWER OF DR. JOHN KAPOOR RELATED TO HIS OWNERSHIP STAKE IN COMPANY.  Full Article

Insys Therapeutics Q4 Loss Per Share $0.65
Friday, 9 Mar 2018 

March 8 (Reuters) - Insys Therapeutics Inc ::INSYS THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 RESULTS.Q4 LOSS PER SHARE $0.65.Q4 REVENUE $31.5 MILLION VERSUS I/B/E/S VIEW $34 MILLION.Q4 EARNINGS PER SHARE VIEW $-0.14 -- THOMSON REUTERS I/B/E/S.  Full Article

Insys' Treatment For Prader-Willi Syndrome Gets ‘Fast Track’ Designation
Tuesday, 26 Dec 2017 

Dec 26 (Reuters) - Insys Therapeutics Inc ::FDA GRANTS INSYS THERAPEUTICS ‘FAST TRACK’ DESIGNATION FOR CANNABIDIOL (CBD) ORAL SOLUTION AS INVESTIGATIONAL TREATMENT FOR PRADER-WILLI SYNDROME.INSYS THERAPEUTICS - PLAN TO START CLINICAL DEVELOPMENT PROGRAM FOR CANNABIDIOL ORAL SOLUTION IN LATE Q1 OF 2018.  Full Article

Insys Therapeutics Inc - ‍Study Is Expected To Be Completed In Late 2018 For Of Cbd Oral Solution-A​
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Insys Therapeutics Inc ::INSYS THERAPEUTICS INITIATES PHASE 2 CLINICAL TRIAL OF CANNABIDIOL (CBD) ORAL SOLUTION FOR TREATMENT OF REFRACTORY CHILDHOOD ABSENCE EPILEPSY IN PEDIATRIC PATIENTS.INSYS THERAPEUTICS INC - ‍STUDY IS EXPECTED TO BE COMPLETED IN LATE 2018 FOR OF CBD ORAL SOLUTION-A​.  Full Article

Insys Therapeutics' NDA For Buprenorphine Sublingual Spray Accepted By FDA
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - Insys Therapeutics Inc ::FDA ACCEPTS NEW DRUG APPLICATION (NDA) FOR BUPRENORPHINE SUBLINGUAL SPRAY FROM INSYS THERAPEUTICS.SAYS ‍UNDER PDUFA, FDA HAS SET TARGET DATE OF JULY 28, 2018 TO COMPLETE REVIEW OF NDA FOR BUPRENORPHINE SUBLINGUAL SPRAY​.SAYS ‍DATA FROM RECENTLY COMPLETED 7-DAY SAFETY & TOLERABILITY STUDY TO BE SUBMITTED TO FDA IN Q1 2018, MAY IMPACT PDUFA DATE​.  Full Article

Insys Therapeutics reports Q3 loss per share of $2.30
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Insys Therapeutics Inc :Insys therapeutics reports third quarter 2017 results.Q3 loss per share $2.30.Q3 revenue $48.9 million.Q3 revenue view $35.5 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S.Insys therapeutics inc qtrly ‍net revenue was unfavorably impacted by approximately $5 million due to product returns​.Insys therapeutics inc qtrly ‍ gross revenue was $48.9 million, resulting in net revenue of $30.7 million​.  Full Article

Insys Therapeutics provides update on NASDAQ trading hold
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Insys Therapeutics Inc ::Insys Therapeutics provides update on NASDAQ trading hold.Subsequent to trading hold placed on stock on Thursday after market close, received series of questions on Friday from NASDAQ​.Questions received from NASDAQ on Oct 27 have been addressed, co is awaiting response from NASDAQ regarding resumption of trading​.  Full Article

Florida doctor admits taking kickbacks from Insys, others

June 4 A Florida doctor has admitted, as part of a plea deal, that he received kickbacks from Insys Therapeutics Inc in exchange for writing prescriptions for a powerful fentanyl-based pain medicine.